Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918552 · ClinicalTrials.gov registry record · Phase 2
Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02918552 is a Phase 2 study that has completed, run by Gladwin, Mark, MD. The registered enrollment target is 15 participants.
The verdict
NCT02918552, a Phase 2 study, has completed, sponsored by Gladwin, Mark, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a randomized double blinded controlled trial of 20-40 mg sodium nitrite tid in subjects with HFpEF. Primary outcomes are measures of physical function with non-invasive and invasive cardiopulmonary exercise testing, and fatigability, skeletal muscle bioenergetics, serology including inflammatory markers and platelet bioenergetics, quality of life measures.
Interventions
- DRUG Control
- DRUG sodium nitrite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918552
The ClinicalTrials.gov registry entry for NCT02918552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gladwin, Mark, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT02918552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918552 about?
NCT02918552 is a clinical study titled "Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction". This is a randomized double blinded controlled trial of 20-40 mg sodium nitrite tid in subjects with HFpEF. Primary outcomes are measures of physical function with non-invasive and invasive cardiopulmonary exercise testing, and fatigability, skeletal muscle bioenergetics, serology including inflamma...
What is the current status of trial NCT02918552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-04-03. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT02918552?
The interventions under investigation include: Control (DRUG), sodium nitrite (DRUG).
Who is sponsoring clinical trial NCT02918552?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.